[{"orgOrder":0,"company":"University of Yaounde 1","sponsor":"World Health Organization | Gates Malaria Partnership","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CAMEROON","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Artesunate","moa":"antimalarials (artemisin dervatives)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University of Yaounde 1","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Yaounde 1 \/ World Health Organization | Gates Malaria Partnership","highestDevelopmentStatusID":"10","companyTruncated":"University of Yaounde 1 \/ World Health Organization | Gates Malaria Partnership"},{"orgOrder":0,"company":"Kenya Medical Research Institute","sponsor":"Dafra Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"KENYA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Artesunate","moa":"antimalarials (artemisin dervatives)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Kenya Medical Research Institute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kenya Medical Research Institute \/ Dafra Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Kenya Medical Research Institute \/ Dafra Pharma"},{"orgOrder":0,"company":"National Institute for Medical Research, Tanzania","sponsor":"Muhimbili University of Health and Allied Sciences | World Health Organization","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TANZANIA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Artesunate","moa":"antimalarials (artemisin dervatives)","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"National Institute for Medical Research, Tanzania","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute for Medical Research, Tanzania \/ Muhimbili University of Health and Allied Sciences | World Health Organization","highestDevelopmentStatusID":"11","companyTruncated":"National Institute for Medical Research, Tanzania \/ Muhimbili University of Health and Allied Sciences | World Health Organization"},{"orgOrder":0,"company":"Nepal Health Research Council","sponsor":"World Health Organization","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NEPAL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Artesunate","moa":"antimalarials (artemisin dervatives)","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Nepal Health Research Council","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nepal Health Research Council \/ World Health Organization","highestDevelopmentStatusID":"11","companyTruncated":"Nepal Health Research Council \/ World Health Organization"},{"orgOrder":0,"company":"Oxford University Clinical Research Unit, Vietnam","sponsor":"World Health Organization","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"VIETNAM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Artesunate","moa":"antimalarials (artemisin dervatives)","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Oxford University Clinical Research Unit, Vietnam","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oxford University Clinical Research Unit, Vietnam \/ World Health Organization","highestDevelopmentStatusID":"8","companyTruncated":"Oxford University Clinical Research Unit, Vietnam \/ World Health Organization"},{"orgOrder":0,"company":"Shin Poong Pharm Co Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Artesunate","moa":"antimalarials (artemisin dervatives)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Shin Poong Pharm Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shin Poong Pharm Co Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shin Poong Pharm Co Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Shin Poong Pharm Co Ltd","sponsor":"Medicines for Malaria Venture","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Artesunate","moa":"antimalarials (artemisin dervatives)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Shin Poong Pharm Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shin Poong Pharm Co Ltd \/ Medicines for Malaria Venture","highestDevelopmentStatusID":"10","companyTruncated":"Shin Poong Pharm Co Ltd \/ Medicines for Malaria Venture"},{"orgOrder":0,"company":"Shin Poong Pharm Co Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Artesunate","moa":"antimalarials (artemisin dervatives)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Shin Poong Pharm Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shin Poong Pharm Co Ltd \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shin Poong Pharm Co Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Artesunate","moa":"antimalarials (artemisin dervatives)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"University of Oxford","sponsor":"World Health Organization","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Artesunate","moa":"antimalarials (artemisin dervatives)","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Oxford \/ World Health Organization","highestDevelopmentStatusID":"1","companyTruncated":"University of Oxford \/ World Health Organization"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"AbbVie Inc | Apotex Inc | World Health Organization | University of British Columbia | Arch Biopartners","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Artesunate","moa":"antimalarials (artemisin dervatives)","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunnybrook Health Sciences Centre \/ AbbVie Inc | Apotex Inc | World Health Organization | University of British Columbia | Arch Biopartners","highestDevelopmentStatusID":"10","companyTruncated":"Sunnybrook Health Sciences Centre \/ AbbVie Inc | Apotex Inc | World Health Organization | University of British Columbia | Arch Biopartners"},{"orgOrder":0,"company":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","sponsor":"Frantz Viral Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Artesunate","moa":"antimalarials (artemisin dervatives)","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ Frantz Viral Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ Frantz Viral Therapeutics"},{"orgOrder":0,"company":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","sponsor":"Frantz Viral Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Artesunate","moa":"antimalarials (artemisin dervatives)","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Suppository","sponsorNew":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ Frantz Viral Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins \/ Frantz Viral Therapeutics"},{"orgOrder":0,"company":"Johns Hopkins University","sponsor":"Frantz Viral Therapeutics | University of Wisconsin, Madison","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Artesunate","moa":"antimalarials (artemisin dervatives)","graph1":"Oncology","graph2":"Phase I","graph3":"Johns Hopkins University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"Johns Hopkins University \/ Frantz Viral Therapeutics | University of Wisconsin, Madison","highestDevelopmentStatusID":"6","companyTruncated":"Johns Hopkins University \/ Frantz Viral Therapeutics | University of Wisconsin, Madison"},{"orgOrder":0,"company":"UNC Lineberger Comprehensive Cancer Center","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Artesunate","moa":"antimalarials (artemisin dervatives)","graph1":"Oncology","graph2":"Phase I","graph3":"UNC Lineberger Comprehensive Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Pessary","sponsorNew":"UNC Lineberger Comprehensive Cancer Center \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"UNC Lineberger Comprehensive Cancer Center \/ Gilead Sciences"},{"orgOrder":0,"company":"Amivas","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Artesunate","moa":"antimalarials (artemisin dervatives)","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Amivas","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amivas \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amivas \/ Undisclosed"},{"orgOrder":0,"company":"Amivas","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Artesunate","moa":"antimalarials (artemisin dervatives)","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Amivas","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amivas \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amivas \/ Undisclosed"},{"orgOrder":0,"company":"Frantz Viral Therapeutics","sponsor":"Amarex Clinical Research | MD Anderson Cancer Center | Harris Health System | Cleveland Clinic | University of Michigan | Morehouse School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Artesunate","moa":"antimalarials (artemisin dervatives)","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Frantz Viral Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Insert","sponsorNew":"Frantz Viral Therapeutics \/ Amarex Clinical Research | MD Anderson Cancer Center | Harris Health System | Cleveland Clinic | University of Michigan | Morehouse School of Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Frantz Viral Therapeutics \/ Amarex Clinical Research | MD Anderson Cancer Center | Harris Health System | Cleveland Clinic | University of Michigan | Morehouse School of Medicine"},{"orgOrder":0,"company":"Frantz Viral Therapeutics","sponsor":"Cleveland Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Artesunate","moa":"antimalarials (artemisin dervatives)","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Frantz Viral Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Frantz Viral Therapeutics \/ Cleveland Clinic","highestDevelopmentStatusID":"8","companyTruncated":"Frantz Viral Therapeutics \/ Cleveland Clinic"},{"orgOrder":0,"company":"Frantz Viral Therapeutics","sponsor":"Laser Surgery Care | Anal Dysplasia Clinic MidWest","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Artesunate","moa":"antimalarials (artemisin dervatives)","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Frantz Viral Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Frantz Viral Therapeutics \/ Laser Surgery Care | Anal Dysplasia Clinic MidWest","highestDevelopmentStatusID":"8","companyTruncated":"Frantz Viral Therapeutics \/ Laser Surgery Care | Anal Dysplasia Clinic MidWest"},{"orgOrder":0,"company":"Frantz Viral Therapeutics","sponsor":"Amarex Clinical Research | University of California, San Francisco | Anal Dysplasia Clinic MidWest | Laser Surgery Care","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Artesunate","moa":"antimalarials (artemisin dervatives)","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Frantz Viral Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"Frantz Viral Therapeutics \/ Amarex Clinical Research | University of California, San Francisco | Anal Dysplasia Clinic MidWest | Laser Surgery Care","highestDevelopmentStatusID":"8","companyTruncated":"Frantz Viral Therapeutics \/ Amarex Clinical Research | University of California, San Francisco | Anal Dysplasia Clinic MidWest | Laser Surgery Care"},{"orgOrder":0,"company":"Amivas","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Artesunate","moa":"antimalarials (artemisin dervatives)","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Amivas","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amivas \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amivas \/ Undisclosed"},{"orgOrder":0,"company":"Fiocruz","sponsor":"Pan American Health Organization | Ministry of Health, Brazil | University of Sao Paulo","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Artesunate","moa":"antimalarials (artemisin dervatives)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Fiocruz","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fiocruz \/ Pan American Health Organization | Ministry of Health, Brazil | University of Sao Paulo","highestDevelopmentStatusID":"9","companyTruncated":"Fiocruz \/ Pan American Health Organization | Ministry of Health, Brazil | University of Sao Paulo"},{"orgOrder":0,"company":"Metanoic Health Ltd.","sponsor":"Clinical Research Malaysia","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Artesunate","moa":"ATP2A1 | SERCA2","graph1":"Oncology","graph2":"Phase II","graph3":"Metanoic Health Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Metanoic Health Ltd. \/ Clinical Research Malaysia","highestDevelopmentStatusID":"8","companyTruncated":"Metanoic Health Ltd. \/ Clinical Research Malaysia"},{"orgOrder":0,"company":"Metanoic Health Ltd.","sponsor":"Clinical Research Malaysia","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Artesunate","moa":"ATP2A1 | SERCA2","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Metanoic Health Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Metanoic Health Ltd. \/ Clinical Research Malaysia","highestDevelopmentStatusID":"8","companyTruncated":"Metanoic Health Ltd. \/ Clinical Research Malaysia"},{"orgOrder":0,"company":"Mangalam Drugs & Organics Ltd","sponsor":"Medicines for Malaria Venture","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Funding","leadProduct":"Pyronaridine Tetraphosphate","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Mangalam Drugs & Organics Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mangalam Drugs & Organics Ltd \/ Medicines for Malaria Venture","highestDevelopmentStatusID":"15","companyTruncated":"Mangalam Drugs & Organics Ltd \/ Medicines for Malaria Venture"}]
Find Clinical Drug Pipeline Developments & Deals for Artesunate
Details :
Artesunate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Malaria.
Details :
Artesunate is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Colonic Neoplasms.
Details :
Artesunate is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Uterine Cervical Dysplasia.
Details :
Artesunate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Cytomegalovirus Infections.
Details :
Artesunate Amivas (artesunate) for Injection is an antimalarial indicated for the initial treatment of severe malaria in adult and pediatric patients.
Details :
The grant will support research and development efforts aimed at improving the technology and efficiency of pyronaridine production for pyronaridine-artesunate combination therapy, Pyramax.
Details :
Artesunate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Anal Squamous Intraepithelial Lesions.
Details :
Artesunate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Uterine Cervical Neoplasms.
Details :
Artesunate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Vulvar Diseases.
Details :
Artesunate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of COVID-19.
Reset All
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
